Takeover bid for Arana
Friday, 27 February, 2009
Arana Therapeutics is in discussions with an unnamed party about a possible takeover bid for the cash-rich company.
Arana, itself the result of a merger between Evogenix and Peptech, has a full and promising pipeline and a very strong cash position of $175 million.
It discontinued its age-related macular degeneration project PMX53 recently, but has strong candidates in inflammatory diseases. Lead candidate ART621, an anti-TNF antibody, is nearing the end of a Phase II trial for psoriasis and is beginning Phase II for rheumatoid arthritis.
The company’s market capitalisation is a very healthy $190 million and its finances strong enough to have carried out a share buy-back.
The company said it would make an announcement on both the bid and the search for a new CEO in due course.
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
Neurosensing/neurostimulation implants session to be held on Monday
On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...
argenx and Monash University partner against autoimmune diseases
To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...
